COMP <GO>
CRI vs PG // REVENUE GROWTH (YOY)
Carter's Inc. (NYSE) VS. Procter & Gamble Company (NYSE) • 15-METRIC TALLY: CRI 5
— PG 7
▲ REVENUE GROWTH (YOY) LEADER: CRI
LAST: $31.54 (-5.51%) • MKT CAP: $1.23B
revenue-growth
1.90%
LAST: $161.57 (+0.61%) • MKT CAP: $372.21B
revenue-growth
0.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRI VS. PG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRI | PG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.40% | 51.20% | -5.80 | PG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.30% | 25.40% | -14.10 | PG | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.9x | 16.2x | -9.30 | CRI | /valuation <GO> |
| Free Cash Flow Yield | 5.60% | 3.77% | +1.83 | CRI | /fcf-yield <GO> |
| Operating Margin | 5.00% | 24.30% | -19.30 | PG | /operating-margins <GO> |
| Net Profit Margin | 3.20% | 19.00% | -15.80 | PG | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 1.90% | 0.30% | +1.60 | CRI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 4.60% | 2.65% | +1.95 | CRI | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.63 | 5.59 | -2.96 | PG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.1 | 60.3 | -6.20 | PG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.87 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.4x | 21.7x | -9.30 | CRI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.23B | $372.21B | -$370.99B | PG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRI REV | PG REV | CRI GROSS % | PG GROSS % | CRI FCF | PG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.90B | $84.28B | 45.4% | 51.2% | $68.6M | $14.04B |
| FY 2024 | $2.84B | $84.04B | 48.0% | 51.4% | $242.6M | $16.52B |
| FY 2023 | $2.95B | $82.01B | — | — | $529.1M | $13.16B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRI // BETA —
PG // BETA 0.87